Family history predicts major adverse cardiovascular events (MACE) in young adults with psoriasis - 20/07/16
, Louise E. Bruun, MD b, Lotus Mallbris, MD, PhD c, Gunnar H. Gislason, MD, PhD b, d, e, Lone Skov, MD, PhD, DMSc a, Jashin J. Wu, MD f, Peter R. Hansen, MD, PhD, DMSc bAbstract |
Background |
Patients with psoriasis may have increased risk of major adverse cardiovascular (CV) events (MACE), and a family history of CV disease (CVD) is an independent risk factor for MACE.
Objective |
We investigated the risk of first-time MACE in patients with psoriasis with or without a family history of CVD.
Methods |
Between January 1, 1997, and December 31, 2011, we identified 2,722,375 individuals, including 25,774 and 4504 patients with mild and severe psoriasis, through administrative registers. Incidence rate ratios were estimated by Poisson regression.
Results |
Mean baseline age was 26.6 (SD 8.6) years. A family history of CVD was found among 16,080 (62.4%) and 3009 (66.8%) patients with mild and severe psoriasis, respectively. In patients with psoriasis and a family history of CVD, the adjusted incidence rate ratios (95% CI) of MACE were 1.28 (1.12-1.46) and 1.62 (1.14-2.30) for mild and severe disease, respectively. In patients with psoriasis but without a family history of CVD, there was no increased risk of MACE.
Limitations |
Results may not apply to late-onset psoriasis.
Conclusions |
A family history of CVD predicted the risk of first-time MACE in young adults with psoriasis. The findings call for increased focus on a family history of CVD in CV risk assessment of patients with psoriasis.
Le texte complet de cet article est disponible en PDF.Key words : cardiovascular disease, epidemiology, family history, inflammation, psoriasis
Abbreviations used : CI, CV, CVD, ICD-10, IRR, MACE, MI
Plan
| Funding sources: None for this study. Grants unrelated to this study are listed in the disclosures below. |
|
| Disclosure: Grants unrelated to the content of this article were received from Pfizer (Dr Egeberg) and the LEO Foundation (Dr Hansen). An similarly unrelated unrestricted research scholarship from the Novo Nordisk Foundation was received by Dr Gislason. Dr Mallbris is currently employed by Eli Lilly. Dr Skov has received consultancy and/or speaker honoraria from Abbvie, Pfizer, Janssen-Cilag, Merck Sharp & Dohme, and Leo Pharma and is a member of the advisory boards of Abbvie, Pfizer, Janssen-Cilag, Merck Sharp & Dohme, Eli Lilly, Celgene, and Novartis. Dr Wu received research funding from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Coherus Biosciences, Dermira, Eli Lilly, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Sandoz, and Sun Pharmaceutical Industries; he is a consultant for AbbVie, Amgen, Celgene, Dermira, Eli Lilly, Pfizer, Regeneron, and Sun Pharmaceutical Industries. This research was performed independently through the authors' academic university affiliations. The funding source had no influence on data collection, no access to the data, and no influence on the decision to submit. Dr Bruun disclosed no funding sources. |
Vol 75 - N° 2
P. 340-346 - août 2016 Retour au numéro
Article précédent
- Assessment of the risk of cardiovascular disease in patients with rosacea
- Alexander Egeberg, Peter R. Hansen, Gunnar H. Gislason, Jacob P. Thyssen
- New insights into folliculotropic mycosis fungoides (FMF): A single-center experience
- Emmilia Hodak, Iris Amitay-Laish, Lihi Atzmony, Hadas Prag-Naveh, Natalia Yanichkin, Aviv Barzilai, Ruben Kershenovich, Meora Feinmesser
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?